HLA-A*24: 02 associated with lamotrigine-induced cutaneous adverse drug reactions. Issue 52 (24th December 2020)

• Record Type: Journal Article
• Authors: Li, Wanshu; Wang, Jie; Lin, Hangjuan; Shen, Gang
• Other Names: Albadrany. Yasser section editor.
• Is Part Of: Medicine. Volume 99:Issue 52(2020)
• Publication Date: 2020-12-24
• Subjects: cutaneous adverse drug reactions -- human leukocyte antigen-A*24:02 -- lamotrigine -- meta-analysis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000023929
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Several studies demonstrated a connection between human leukocyte antigen (HLA)-B*1502 and lamotrigine (LTG)-induced cutaneous adverse drug reactions (cADRs). The correlation between the HLA-A*24:02 and LTG-cADRs remains controversial. To examine the associations between HLA-A*24:02 and LTG-cADRs, we conducted a systematic review and meta-analysis. Methods: We performed a comprehensive search of the literature in several electronic database systems including Cochrane Library, EMBASE and PubMed from inception to January 2020. Review Manager was used to compare the frequencies of HLA-A*24:02 carriers between the subgroups. Results: A total of 5 studies were eligible, including 197 LTD-cADRs, 396 LTD-tolerant controls, and 2068 population controls. Compared with the LTG-tolerant controls, there was a statistically significant association between the HLA-A*24:02 allele and LTG-induced cADRs (odds ratios: 1.94, 95% confidence intervals 1.06–3.54; P = .03). Compared with the general population, the relationship between the HLA-A*24:02 genotype and LTG-induced cADRs was statistically significant (summary odds ratios: 2.12, 95% confidence intervals 1.04–4.30; P = .04). Conclusions: HLA-A*24:02 may be a risk factor for LTG-cADRs.